Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Cyprotex introduces new assay range for bespoke ADME and PK services

Cyprotex : 07 April, 2008  (New Product)
Cyprotex has introduced a new product range, Cloe Select, which is a portfolio of bespoke studies that can be customised to individual customer requirements.
The new range complements the current range of Cloe Screen assays to provide ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic solutions from early discovery through to later stage development projects. As with Cloe Screen, Cloe Select meets the criteria set by the regulatory guidelines to provide constant confidence in the quality of the data.

The drug discovery and development process represents a number of pre-clinical phases which cover hit to lead, lead optimisation and candidate selection. Cyprotex can now offer a fully integrated solution in the area of ADME and pharmacokinetics throughout this entire process. The company has gained extensive knowledge in our field over the past nine years, which is attributed to investing in high calibre committed scientists and by working with a large and diverse customer base.

Robert Atwater, Cyprotex's chief executive officer, commented on the launch of the new product range. 'Many of our customers rely on us for their ADME projects right from early screening projects through to IND submission. Building these relationships and ensuring that we can offer a flexible and broad range of screening options has been critical in the success of our business.'

Cyprotex is a specialist provider of ADME data and pharmacokinetic predictive services. Our Cloe Screen technology which couples robust protocols with state-of-the-art automation enables Cyprotex to offer an unrivalled combination of high quality, cost effective data with rapid turnaround.

Introducing Cloe Select ensures that Cyprotex can extend its offering to later stage more in-depth studies which require a more flexible approach.

Cyprotex also has extensive expertise in physiologically based pharmacokinetic (PB-PK) modelling and quantitative structure activity relationship (QSAR) modelling techniques under its Cloe Predict service.

In combination, Cloe Screen, Cloe Select and Cloe Predict offer an integrated solution for both experimental screening and prediction, fulfilling the needs of its broad and varied customer base.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo